Sienna Biopharmaceuticals Inc logo

SNNAQ - Sienna Biopharmaceuticals Inc Share Price

$0.005 -0.0  -20.6%

Last Trade - 7:14pm

Sector
Healthcare
Size
Micro Cap
Market Cap £146k
Enterprise Value £-8.33m
Revenue £n/a
Position in Universe 6390th / 6444
Bullish
Bearish
Unlock SNNAQ Revenue
Momentum
Relative Strength (%)
1m +11.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -97.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2019, SiennaBiopharmaceuticals Inc revenues was not reported. Net lossdecreased 47% to $28.6M. Lower net loss reflects Researchand development - Balancing val decrease of 63% to $14.9M(expense). Basic Earnings per Share excluding ExtraordinaryItems increased from -$2.66 to -$1.07.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SNNAQ Revenue Unlock SNNAQ Revenue

Net Income

SNNAQ Net Income Unlock SNNAQ Revenue

Normalised EPS

SNNAQ Normalised EPS Unlock SNNAQ Revenue

PE Ratio Range

SNNAQ PE Ratio Range Unlock SNNAQ Revenue

Dividend Yield Range

SNNAQ Dividend Yield Range Unlock SNNAQ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SNNAQ EPS Forecasts Unlock SNNAQ Revenue
Profile Summary

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. It also advancing multiple product candidates derived from Topical by Design platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. It's SNA-120 is a first-in-class inhibitor of Tropomyosin receptor kinase A, or TrkA, in Phase IIb clinical development for the treatment of pruritus, or itch, associated with psoriasis, as well as for psoriasis itself. It's SNA-125 is a topical Janus kinase 3 (JAK3)/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and pruritus. Nonclinical studies have demonstrated anti-inflammatory activity in an animal model, and a favorable safety profile.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated July 27, 2010
Public Since July 27, 2017
No. of Shareholders: 91
No. of Employees: 13
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 30,907,542
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SNNAQ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SNNAQ
Upcoming Events for SNNAQ
Frequently Asked Questions for Sienna Biopharmaceuticals Inc
What is the Sienna Biopharmaceuticals Inc share price?

As of 7:14pm, shares in Sienna Biopharmaceuticals Inc are trading at $0.005, giving the company a market capitalisation of £146k. This share price information is delayed by 15 minutes.

How has the Sienna Biopharmaceuticals Inc share price performed this year?

Shares in Sienna Biopharmaceuticals Inc are currently trading at $0.005 and the price has moved by -97.53% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sienna Biopharmaceuticals Inc price has moved by -97.85% over the past year.

What are the analyst and broker recommendations for Sienna Biopharmaceuticals Inc?

Of the analysts with advisory recommendations for Sienna Biopharmaceuticals Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sienna Biopharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Sienna Biopharmaceuticals Inc next release its financial results?

Sienna Biopharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the Sienna Biopharmaceuticals Inc dividend yield?

Sienna Biopharmaceuticals Inc does not currently pay a dividend.

Does Sienna Biopharmaceuticals Inc pay a dividend?

Sienna Biopharmaceuticals Inc does not currently pay a dividend.

When does Sienna Biopharmaceuticals Inc next pay dividends?

Sienna Biopharmaceuticals Inc does not currently pay a dividend.

How do I buy Sienna Biopharmaceuticals Inc shares?

To buy shares in Sienna Biopharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sienna Biopharmaceuticals Inc?

Shares in Sienna Biopharmaceuticals Inc are currently trading at $0.005, giving the company a market capitalisation of £146k.

Where are Sienna Biopharmaceuticals Inc shares listed? Where are Sienna Biopharmaceuticals Inc shares listed?

Here are the trading details for Sienna Biopharmaceuticals Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: SNNAQ
What kind of share is Sienna Biopharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Sienna Biopharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sienna Biopharmaceuticals Inc share price forecast 2020?

Shares in Sienna Biopharmaceuticals Inc are currently priced at $0.005. At that level they are trading at 317% discount to the analyst consensus target price of 0.00.

Analysts covering Sienna Biopharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.5 for the next financial year.

How can I tell whether the Sienna Biopharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sienna Biopharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -55.29%. At the current price of $0.005, shares in Sienna Biopharmaceuticals Inc are trading at -47.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sienna Biopharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Sienna Biopharmaceuticals Inc.

Who are the key directors of Sienna Biopharmaceuticals Inc?

Sienna Biopharmaceuticals Inc's management team is headed by:

Robert More - DRC
Frederick Beddingfield - PRE
James Hindman - DRC
Keith Leonard - CHM
Kristina Burow - DRC
Dennis Fenton - DRC
Alexander Azoy - CFO
Sean Andrews - VPR
Who are the major shareholders of Sienna Biopharmaceuticals Inc?

Here are the top five shareholders of Sienna Biopharmaceuticals Inc based on the size of their shareholding:

ARCH Venture Partners Venture Capital
Percentage owned: 18.76% (5.80m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 13.88% (4.29m shares)
Fidelity Growth Company Fund Mutual Fund
Percentage owned: 6.09% (1.88m shares)
Beddingfield (Frederick C III) Individual Investor
Percentage owned: 2.53% (781k shares)
Fidelity Series Growth Company Fund Mutual Fund
Percentage owned: 1.96% (606k shares)
Similar to SNNAQ
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.